Status:
COMPLETED
Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass
Lead Sponsor:
Lars Olaf Cardell
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
52 patients that had previously participated in the RDBPC study of intralymphatic immunotherapy (ILIT) with 2 concomitant allergens, birch and grass, with NCT02423707, were eligible for an open follow...
Detailed Description
Bakground: Intralymphatic immunotherapy has been proposed as a new, more effective, modality for allergy immunotherapy. With ultrasound- guided injections into the lymph node the allergen is injected ...
Eligibility Criteria
Inclusion
- \- Moderate to severe allergic rhinitis to birch and grass pollen defined with a positive skin prick test and elevated allergen specific IgE antibodies
Exclusion
- uncontrolled or perennial asthma
- other pulmonary disease
- known autoimmune or collagen disease
- chronic infection
- other significant disease
- severe atopic dermatitis
- use of beta blockers or angiotensin converting enzyme inhibitors as antihypertensive medications
- symptomatic sensitization to house dust mite or furry animals with daily exposure
- chronic upper airways disease
- pregnancy
- nursing
- obesity with BMI \>30
- withdrawn informed consent
Key Trial Info
Start Date :
May 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04296474
Start Date
May 15 2018
End Date
July 1 2022
Last Update
September 21 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergic Unit at the Department of Oto-Rhino-Laryngology at Skåne University Hospital Lund
Lund, Sweden, 221 85
2
Allergic Unit at the Department of Oto-Rhino-Laryngology at Skåne University Hospital Malmö
Malmo, Sweden, 20502
3
ENT department, Karolinska University Hospital
Stockholm, Sweden, 141 86